Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
All active doses produced statistically significant improvements in satisfying sexual events, Female Sexual Function Index desire domain scores, and Female Sexual Distress Scale scores compared to placebo establishing the dose-response data that determined the final 1.75 mg dose selected for Phase III pivotal trials and FDA submission
Efficacy and safety outcomes are summarized in Table 4
Sometimes, small clinical adjustments lead to noticeable progress quickly
Based on the evidence reviewed in this analysis: The regulatory landscape has shifted
US$ 26.21
US$ 28.39
US$ 29.32
